Click on any of the names below to read the profile.
Medical School at the University of Zimbabwe, Harare, Zimbabwe, Residency at Case Western Reserve University in Cleveland, Ohio, and Fellowship at the Cleveland Clinic, Cleveland, Ohio. Dr. Gumbo has been both a bench scientist and clinician, has developed several laboratory models for fungal, parasitic, bacterial and viral infections, using animal models, human challenge models, and in vitro dynamic models such as the hollow fiber model of TB, non-tuberculous mycobacteria, and cancer. He has also developed several mathematical models for translation from the laboratory to patients in the area of therapeutics and quantitative translational pharmacology, and for characterizing disease progression and the immune system in patients based on next generation sequencing and mathematics. He has received research funding from several national organizations such as the US NIH, the South African Medical Research Council, and other private-public partnerships.
Dr. Gumbo is the recipient of numerous awards. His pre-clinical and clinical work has been used to identify now licensed clinical doses of three antifungal drugs called echinocandins, anti-tuberculosis [TB] compounds by the WHO Global TB program and by national tuberculosis [TB] programs in numerous countries, currently used hospital diagnostics of microscoporidia [a parasitic infection in that causes diarrhea immunocompromised patients], the design of new anti-TB drug regimens for children and adults, and together with his team recently identified and characterized safe inhibitors of the fundamental physiologic pathway essential to embryogenesis, organ positioning, healing, and fibrosis, called sonic hedgehog signaling.
Dr. Gumbo is also a published poet.
Michael Kahil graduated from Sam Houston State University with a B.A. in Finance and Minor in Accounting. He received continued formal credit training as an analyst prior to moving into management. He has become well known to his peers as the go-to for questions with company formations and raising capital. Currently he has several primary roles. He is first, a Middle market banker. Michael has 12 years in commercial banking, focused primarily in real estate and C&I. He served as the Lead Analyst for two mid sized banks before moving into the lending role for the commercial group and then moved into VP corporate banking role with a regional sized bank.
Over last 5 years he has managed over $200M in portfolio customers and has sourced $500M in new debt obligations that he either originated the debt or helped place with other institutions. Most recently, Michael serves on the board of multiple startup companies as an advisor and continues to work as a private consultant to companies in transition looking to take very large steps in their business cycles or to make large acquisitions using debt acquisition or private equity.
Michael has built and directed problem-solving and organizational development teams for a variety of companies in start-up and transitional phases. He specializes in helping companies identify internal obstacles to growth/profitability. He also works with these companies to help focus their attention on strategic growth. Within these companies, Michael builds teams and implements programs to allow those companies to continue growing and stay in compliance with their newly found equity and debt sources.